Red X iconGreen tick iconYellow tick icon

Barry HockScientific Officer
Honorary Research Fellow

BSc(Hons), PhD(Otago)

Email barry.hock@otago.ac.nz
Tel +64 3 244 1106

Publications

Permain, J., Hock, B., Eglinton, T., & Purcell, R. (2024). Functional links between the microbiome and the molecular pathways of colorectal carcinogenesis. Cancer & Metastasis Reviews. Advance online publication. doi: 10.1007/s10555-024-10215-5 Journal - Research Article

Keating, P. E., Hock, B. D., Chin, P. K. L., O'Donnell, J. L., & Barclay, M. L. (2024). Evaluation of the homogenous mobility shift assay for infliximab and adalimumab anti-drug antibody detection in the clinical laboratory. Therapeutic Drug Monitoring. Advance online publication. doi: 10.1097/ftd.0000000000001200 Journal - Research Article

Barclay, M. L., Keating, P. E., Hock, B. D., Chin, P. K. L., & O'Donnell, J. L. (2023). Infliximab or adalimumab antidrug-antibody complex size has more clinical value than concentration. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Annual Scientific Meeting: Transformational Pharmacology and Toxicology. 235. Retrieved from https://www.asceptasm.com Conference Contribution - Published proceedings: Abstract

Barclay, M. L., Keating, P. E., Hock, B. D., Smith, S. M., Chin, P. K. L., & O'Donnell, J. L. (2023). Four-year review of New Zealand laboratory infliximab and adalimumab concentration results indicating high potential for improved dosing. Proceedings of the Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT) Annual Scientific Meeting: Transformational Pharmacology and Toxicology. P513. Retrieved from https://www.asceptasm.com Conference Contribution - Published proceedings: Abstract

Keating, P. E., Hock, B. D., Smith, S. M., Chin, P. K. L., O'Donnell, J. L., & Barclay, M. L. (2023). Four-year review of New Zealand laboratory infliximab and adalimumab concentration results indicating potential for improved dosing [Brief communication]. Internal Medicine Journal, 53(11), 2123-2127. doi: 10.1111/imj.16264 Journal - Research Other

Back to top